Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06982105 · ClinicalTrials.gov registry record · Phase 4
Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
A Phase 4 study of Septic Arthritis and Methicillin-resistant Staphylococcus Aureus, sponsored by Indiana University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06982105 is a Phase 4 study of Septic Arthritis and Methicillin-resistant Staphylococcus Aureus that is actively recruiting participants, run by Indiana University. The registered enrollment target is 100 participants, below the 225-participant average among 6 other Septic Arthritis trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06982105, a Phase 4 study of Septic Arthritis and Methicillin-resistant Staphylococcus Aureus, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if trimethoprim-sulfamethoxazole (TMP-SMX) works to treat invasive infections due to methicillin-resistant Staphylococcus aureus (MRSA) in children. It will also learn about the safety of TMP-SMX in the treatment of children with invasive MRSA infections. The main questions it aims to answer are: -Is TMP-SMX effective at successfully treating children with invasive infections due to MRSA? What are the side effects of TMP-SMX in children taking it for invasive infections due to MRSA? Researchers will compare TMP-SMX to a clindamycin (a commonly prescribed antibiotic for the treatment of MRSA in children) to see if TMP-SMX works better, worse or the same as clindamycin for children with invasive infections due to MRSA. Participants will: Take TMP-SMX or clindamycin for the treatment of their invasive infection due to MRSA. Will follow up with the provider treating their invasive infection at the discretion of the treating provider. Keep a diary of their symptoms and any side effects of the medicine
Conditions Studied
Interventions
- DRUG Trimethoprim Sulfamethoxazole
Study Locations (1)
Indiana
- Riley Hospital for Children - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2027-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06982105
The ClinicalTrials.gov registry entry for NCT06982105 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 225-participant average among 6 other Septic Arthritis trials with a reported enrollment target (56% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Septic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Trimethoprim Sulfamethoxazole is the first listed.
NCT06982105 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT06982105 about?
NCT06982105 is a clinical study titled "Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections". The goal of this clinical trial is to learn if trimethoprim-sulfamethoxazole (TMP-SMX) works to treat invasive infections due to methicillin-resistant Staphylococcus aureus (MRSA) in children. It will also learn about the safety of TMP-SMX in the treatment of children with invasive MRSA infections. ...
What is the current status of trial NCT06982105?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2025-05-20. Estimated completion is 2027-06.
What conditions does trial NCT06982105 study?
This clinical trial studies the following conditions: Septic Arthritis, Methicillin-resistant Staphylococcus Aureus, Osteomyelitis Acute, Orbital Cellulitis, Facial Cellulitis.
What interventions are being tested in trial NCT06982105?
The interventions under investigation include: Trimethoprim Sulfamethoxazole (DRUG).
Who is sponsoring clinical trial NCT06982105?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06982105 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Septic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections
COMPLETED · Phase 4
-
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
RECRUITING · NA
-
Retention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN)
RECRUITING · NA
-
Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients
COMPLETED
-
Ankle Joint Replacement Outcomes Study
COMPLETED
-
Personalized Immunotherapeutic for Antibiotic-resistant Infection
COMPLETED · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.